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Key Points
•Chaperones, antioxi-
dants, iron-
sequestering proteins,
and cathepsin S
exhibited increased
abundance in thalasse-
mic EVs.
•Haptoglobin and
hemopexin are reduced
in thalassemic patients’
EVs, reflecting hemoly-
sis. These could be
used as clinical
biomarkers.
Hemoglobin E (HbE)/b-thalassemia has a wide spectrum of clinical manifestations that
cannot be explained purely by its genetic background. Circulating extracellular vesicles
(EVs) are one factor that likely contributes to disease severity. This study has explored the
differences in protein composition and quantity between EVs from HbE/b-thalassemic
patients and healthy individuals. We used tandem mass tag labeling mass spectrometry to
analyze the EV proteins isolated from the plasma of 15 patients compared with the controls.
To reduce biological variation between individuals, the EV proteins isolated from randomly
assigned groups of 5 HbE/b-thalassemic patients were pooled and compared with 5 pooled
age- and sex-matched controls in 3 separate experiments. Alpha hemoglobin–stabilizing
protein had the highest fold increase. Catalase, superoxide dismutase, T-complex proteins,
heat shock proteins, transferrin receptor, ferritin, and cathepsin S were also upregulated in
thalassemic circulating EVs. Importantly, haptoglobin and hemopexin were consistently
reduced in patients’ EVs across all data sets, in keeping with the existing hemolysis that
occurs in thalassemia. The proteomic data analysis of EV samples isolated from 6 individual
HbE/b-thalassemic patients and western blotting results corroborated these ﬁndings. In
conclusion, we have successfully identiﬁed consistent alterations of protein quantity
between EVs from HbE/b-thalassemic and healthy individuals. This work highlights
haptoglobin, hemopexin, and cathepsin S as potential clinically relevant biomarkers for
levels of hemolysis and inﬂammation. Monitoring of these plasma proteins could help in the
clinical management of thalassemia.
Introduction
Thalassemia is the most common single gene disorder of red blood cells (RBCs) resulting in ineffective
erythropoiesis and hemolytic anemia. The disease arises from either totally or partially impaired synthesis
of the a- and/or b-globin chain. The main pathophysiology of b-thalassemia is a reduction of b-globin
chain production, which causes the unpaired a-globin chains to form an irreversible hemichrome that
precipitates on the erythroid membrane.1,2 The hemichrome or availability of free iron via the Fenton
reaction results in the production of reactive oxygen species (ROS) that initiate oxidative stress and cell
membrane damage. Hemoglobin E (HbE) is an abnormal hemoglobin generated due to a cryptic splice
site at codon 26 of exon 1 of the HBB gene (HBB:c.79G.A [p.Glu27Lys]). This mutation has the
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highest prevalence in Southeast Asia,3 and compound heterozy-
gosity for HbE and b-thalassemia is particularly common in
Thailand.3 The compound heterozygosity results in a wide range
of disease severity, from intermediate to severe. Several factors play
a role here, such as incomplete (b1) or complete (b0) loss of the
b-globin chain, association with hereditary persistence of fetal
hemoglobin, the degree of disparity between a- and non–a-globin
chains, the starting onset and requirement for blood transfusion
therapy,4 and also extracellular vesicle (EV) production.5,6 The
numbers of EVs observed in the plasma of thalassemic patients are
4 times higher than in healthy controls; these are thought to be
generated from the severe oxidative stress exposure of thalassemic
red cells7 and are also derived from platelets.8 It is well established
that these EVs are associated with increased clinically significant
procoagulant activity.9-11 This is explained by the combination of
negatively charged phosphatidylserine exposure and activated
tissue factor on the surface of EVs, which together initiate the
coagulation cascade resulting in thrombin generation. In addition,
EVs derived from platelets can induce expression of proinflamma-
tory cytokines and chemokines. Higher amounts of platelets in the
HbE/b-thalassemic patients, particularly the splenectomized pa-
tients, were also reported by Natesirinilkul and colleagues.12
Previous studies of the proteomics profile in EVs in the plasma
released from the platelets and RBCs of b-thalassemic patients
reported a higher level of proteins involved in the oxidative stress
response, for example, catalase, peroxiredoxin 2 (PRDX2), and
heat shock proteins 70 (Hsp70) when compared with healthy
individuals.13,14 In addition, evidence of increased RBC gener-
ation in b-thalassemia was identified, such as detection of
m hemoglobin, which is transcribed from the a gene (HBM) and
usually expressed in cord blood reticulocytes.15
The close association between EV generation and pathophysiology
of HbE/b-thalassemia suggests that the severity spectrum of
clinical manifestations of the patients might be shown in the
composition of EVs. This study aims to use quantitative tandem
mass tag (TMT) coupled with sensitive nano–liquid chromatography
mass spectrometry (nano–LC MS/MS) to explore the proteomic
profiles of EVs to identify alterations in HbE/b-thalassemic patients’
EV constituents compared with controls. The ultimate aim of such
exploration is the identification of potential biomarkers that could be
used to predict the severity of the disease and/or ideally to monitor
requirements for blood transfusion.
Methods
Patients and samples
Ethical approval was obtained from the Institutional Review Board
Committee, Siriraj Hospital (Bangkok, Thailand). Patients and
control individuals enrolled in the study provided written consent
according to the Declaration of Helsinki. Peripheral blood
samples were collected from 15 patients diagnosed with HbE/
b-thalassemia (Table 1) and 15 age- and sex-matched controls in
3.2% citrate tubes. Circulating plasma EVs were isolated using
ultracentrifugation.16,17 Briefly, debris and platelets were removed
from the plasma by centrifugation at 2000g for 10 minutes.
Platelet-free plasma was then centrifuged first at 3000g for 10
minutes and then transferred to a new tube for centrifugation at
100 000g for 60 minutes at 4°C. The supernatant was discarded
and EV pellet resuspended in phosphate-buffered saline (PBS)
and stored at 220°C for shipping frozen to Bristol, United
Kingdom. Long-term EV sample storage was at 280°C.
Proteomic analysis: TMT labeling and high pH
reversed-phase chromatography
To reduce biological variation, EV samples were pooled together
from 5 random individual samples in both the patient and the control
groups, as described previously.18-20 In addition, where sufficient
sample was available, individual patient samples were analyzed
alongside the pooled control samples (Figure 1B). Aliquots of
100 mg of 10 samples per experiment were digested with trypsin
(2.5 mg trypsin per 100 mg of protein; 37°C, overnight), labeled with
TMT reagents according to the manufacturer’s protocol (Thermo
Fisher Scientific, Loughborough, United Kingdom) and the labeled
samples were pooled.
An aliquot of the pooled sample was evaporated to dryness and
resuspended in buffer A (20 mM ammonium hydroxide, pH 10) prior
to fractionation by high pH reversed-phase chromatography using
an Ultimate 3000 LC system (Thermo Fisher Scientific). In brief, the
sample was loaded onto an XBridge BEH C18 column (130A˚,
3.5 mm, 2.1 mm 3 150 mm; Waters, Elstree, United Kingdom) in
buffer A, and peptides were eluted with an increasing gradient
of buffer B (20 mM ammonium hydroxide in acetonitrile, pH 10)
from 0% to 95% over 60 minutes. The resulting fractions were
evaporated to dryness and resuspended in 1% formic acid prior to
analysis by nano-LC MS/MS using an Orbitrap Fusion Tribrid mass
spectrometer (Thermo Scientific).
Nano-LC mass spectrometry
High pH reversed-phase fractions were further fractionated using an
Ultimate 3000 nano high performance LC system in line with an
Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific).
Peptides in 1% (vol/vol) formic acid were injected onto an Acclaim
PepMap C18 nano-trap column (Thermo Scientific). After washing
with 0.5% (vol/vol) acetonitrile, 0.1% (vol/vol) formic acid peptides
were resolved on a 250-mm 3 75-mm Acclaim PepMap C18
reversed-phase analytical column (Thermo Scientific) over a 150-
minute organic gradient, using 7 gradient segments (1%-6% solvent
B over 1 minute, 6%-15% B over 58 minutes, 15%-32% B over 58
minutes, 32%-40% B over 5 minutes, 40%-90%B for 1 minute, held
at 90% B for 6 minutes, and then reduced to 1%B for 1 minute) with
a flow rate of 300 nL per minute. Solvent A was 0.1% formic acid, and
solvent B was aqueous 80% acetonitrile in 0.1% formic acid.
Peptides were ionized by nanoelectrospray ionization at 2.0 kV using
a stainless-steel emitter with an internal diameter of 30 mm (Thermo
Scientific) and a capillary temperature of 275°C.
All spectra were acquired using an Orbitrap Fusion Tribrid mass
spectrometer controlled by Xcalibur 2.0 software (Thermo Scien-
tific) and operated in data-dependent acquisition mode using a
synchronous precursor selection–MS3 workflow. Fourier transform
mass analyzers (FTMS)1 spectra were collected at a resolution of
120 000, with an automatic gain control (AGC) target of 200 000
and a maximum injection time of 50 milliseconds. Precursors were
filtered with an intensity threshold of 5000, according to charge
state (to include charge states 2-7) and with monoisotopic
precursor selection. Previously interrogated precursors were
excluded using a dynamic window (60 seconds 6 10 ppm). The
MS2 precursors were isolated with a quadrupole mass filter set to a
width of 1.2 m/z. Ion-trap tandem mass spectrometry (ITMS2)
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spectra were collected with an AGC target of 10 000, the maximum
injection time of 70 milliseconds, and collision-induced dissociation
collision energy of 35%.
For FTMS3 analysis, the Orbitrap was operated at 50 000 resolution
with an AGC target of 50 000 and a maximum injection time of 105
milliseconds. Precursors were fragmented by high-energy collision
dissociation at a normalized collision energy of 60% to ensure maximal
TMT reporter ion yield. Synchronous precursor selection was enabled
to include up to 5 MS2 fragment ions in the FTMS3 scan.
Proteomics data analysis
The raw data files were processed and quantified using Proteome
Discoverer software v1.4 (Thermo Scientific) and searched against
the UniProt human database (134 169 sequences) using the
SEQUEST algorithm. Peptide precursor mass tolerance was set at
10 ppm, and MS/MS tolerance was set at 0.6 Da. Search criteria
included oxidation of methionine (115.9949) as a variable
modification and carbamidomethylation of cysteine (157.0214)
and the addition of the TMT mass tag (1229.163) to peptide N
termini and lysine as fixed modifications. Searches were performed
with full tryptic digestion, and a maximum of 1 missed cleavage was
allowed. The reverse database search option was enabled, and all
peptide data were filtered to satisfy a false discovery rate of 5%.
Immunoblotting
Protein quantification was measured using the Bradford protein
assay using bovine serum albumin as a standard. EV proteins were
diluted at a 1/1 volume with sodium dodecyl sulfate sample buffer.
The samples were then incubated at 95°C for 3 minutes before being
solubilized with 5% (wt/vol) 2-mercaptoethanol. The samples were
separated on 10% to 12.5% polyacrylamide gels and transferred to
polyvinylidene difluoride membranes. The membranes were blocked
for 1 hour (5% milk plus 0.05% Tween 20 in PBS [PBS-T]), then
the primary antibodies were added and incubated at 4°C overnight.
After sequential PBS-T washing was performed, the secondary anti-
body was added to each membrane and incubated for 1 hour.
Chemiluminescent detection was carried out using ECL Plus reagent
(Western Lightning; PerkinElmer) in Kodak Image Station 4000R.
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Figure 1. Flowchart of methods used for EV isolation and obtained results. From top left, EVs were isolated from 3.2% citrate plasma by differential ultracentrifugation
technique. (A) EVs were analyzed using nanoparticle tracking analysis with Nanosight LM10 (Malvern Instruments Ltd). In the example shown, particle size was between 100
and 200 nm, consistent with the expected size of EVs. (B) Three sets of pooled samples with controls (n 5 5) were analyzed in 3 proteomic experiments by TMT and MS/MS
analysis. Additionally, 4 and 2 individual samples from the first and second sample pools, respectively, were also analyzed separately in the TMT experiments. (C) Gene
Ontology analysis using Fun Rich software v3 on the 3 data sets regarding their cellular components. The majority of the identified proteins were components of EVs: 81.78%,
82.49%, and 80.29% from the first, second, and third data set, respectively. The total number of EV proteins identified was 645 EV proteins with 212 (32.9%) EV proteins
common across the 3 separate experiments.
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Antibodies
Antibodies used for immunoblotting were: anti-a-hemoglobin–
stabilizing protein (anti-AHSP) antibody, a gift from R. Griffiths
(National Health Service Blood and Transplant [NHSBT] Filton);
the anti-catalase (ab16731), anti-hemopexin (ab90947), and anti-
haptoglobin (ab131236), antibodies were all obtained from Abcam
(Cambridge, United Kingdom).
Statistical analysis
The association between severity of anemia in the patients
represented by levels of hemoglobin and ratios of protein abundance
in EV samples was analyzed by Spearman rank correlation using
SPSS software version 16 (SPSS Inc, Chicago, IL).
Results
Proteomic profiling of proteins found in EVs of HbE/
b-thalassemia patients
EVs were isolated from HbE/b-thalassemic and control samples,
as outlined in “Methods.” To reduce biological variation between
individuals, quantitative proteomics of the circulating EVs were
performed across 3 separate sets of pooled patient and
matched- control samples. Five plasma-derived EV samples
were pooled together at the same protein concentration for each
sample, and then analyzed by nano-LC MS/MS. When filtered for
proteins with .1 unique peptide, we identified 685, 1127, and
859 individual proteins for the 3 individual experiments.
Approximately 80% of the proteins detected in each experiment
are known constituents of EVs, matching the Gene Ontology
system (GO:1903561) from the AmiGO version 1.8 database
(Figure 1C; supplemental Tables 3 and 4). The isolated EVs
contained proteins from a mixture of cellular sources, including
platelet proteins and RBC/reticulocyte proteins. Table 2 lists 19
proteins in the EV samples that were consistently more abundant
in the HbE/b-thalassemia patient samples compared with the
controls, across all 3 experiments. There were only 2 proteins
that differentially reduced their abundance in the patient samples
(Table 3) (see supplemental Tables 1 and 2 for the peptides and
peptide spectrum matches of all the identified proteins with
altered abundance).
Proteins that increased their abundance in the patient over control
samples can be categorized according to their molecular functions
as chaperone proteins, proteins involved with iron metabolism,
antioxidant proteins, and erythrocyte-specific proteins (Table 2).
Among these, the protein with the highest ratio difference between
patients and controls was AHSP, a RBC-specific protein that
prevents a-globin precipitation,21 which exhibited between 31- and
47-fold increases in thalassemic EVs. Other chaperone proteins
identified in our study were Hsp70, Hsp90, and T-complex protein 1
subunit a and g. Three antioxidant proteins that were increased
in thalassemic EVs were catalase, superoxide dismutase (SOD1),
and PRDX2. Flavin reductase, a broad specificity oxidoreductase
that catalyzes the nicotinamide adenine dinucleotide phosphate
(NADPH) reduction contributing to heme catabolism and provides
reducing power for the release of ferritin-bound iron, was increased.
Other proteins involved in iron metabolism were also increased
(ferritin and transferrin), alongside carbonic anhydrase 1, trans-
aldolase (a pentose phosphate pathway enzyme) and the erythro-
cyte cytoskeleton proteins spectrin and ankyrin. These dataTa
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strengthen the hypothesis that the circulating plasma EVs are
derived in part from erythrocyte lysis.22 Finally, an increase in the
quantity of cathepsin S, a potent elastolytic protease, was detected
in thalassemic EVs, which may originate from activated myeloid
cells.23
Only 2 proteins, hemopexin and haptoglobin, were consistently and
significantly reduced (12.5- to 25-fold and 7.1- to 20-fold reduction,
respectively) in the patient compared with control EV samples
across the 3 experiments (Table 3). These data are consistent with
the pathophysiology of thalassemia, with the hemolysis causing a
dramatic decrease in these hemoglobin/heme scavengers.
In addition to the pooled samples, where there was sufficient EV
protein sample isolated, individual patient samples were also
included within the same TMTMS experiments. Proteomics analysis
of 6 individual samples across 2 separate experiments corroborated
the pooled results. All of the proteins identified as having increased
quantity in the pooled patient EVs had increased abundance in each
individual sample, namely, AHSP, Hsp70, HspA8, Hsp90, TCP1
subunit a and g, flavin reductase (NADPH), SOD1, catalase,
PRDX2, and ferritin (see details in Table 4). Moreover, the fold
increases of EV protein in the individual samples correlated well with
severity of anemia of the patients. Levels of hemoglobin were used
as an indicator of anemia in the patients. Ratios of antioxidant
proteins, AHSP, Hsp70, and TCP1-a showed statistically signifi-
cant reverse correlation with hemoglobin levels, summarized in
Table 5.
Immunoblotting
The alterations in abundance of catalase, AHSP, hemopexin, and
haptoglobin were also confirmed in individual samples by western
blot analysis. Two pairs of patients and age- and sex-matched
controls were tested to represent proteins in the EVs of the patient
and control groups (Figure 2). The upregulation of AHSP and
catalase was demonstrated in patient samples when compared with
their controls. Hemopexin and haptoglobin were markedly de-
creased in both cases.
Thalassemic EV plasma adsorption test
We speculated that the depletion of both hemopexin and
haptoglobin from the EVs observed in this study is an indicator of
their continual clearance from patient’s plasma, which was in turn
reflected in the amount of these proteins associated with EVs. To
test this hypothesis, thalassemic patients’ EV pellets were washed
and then incubated for 72 hours with EV-depleted normal fresh
plasma. Using western blotting, we observed that incubation of
normal plasma caused the restoration of haptoglobin and hemo-
pexin levels in patients’ EVs (supplemental Figure 1).
Discussion
This study has used quantitative MS to characterize the differences
between EVs produced by HbE/b-thalassemic patients and healthy
controls. In both control and patient samples, the EVs ranged in size
between 100 and 200 nm and ;80% of proteins were known
constituents of EVs (GO:1903561) (Figure 1C), which confirms
that the identity of the samples is circulatory plasma EVs. Many of
the identified proteins, including platelet and erythroid proteins,
were found to be common in EVs across all experiments
(supplemental Table 3). We observed that antioxidant proteins,
chaperone proteins, proteins involving in iron metabolism,Ta
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hemoglobin subunit d, cathepsin S (an inflammatory marker), and
erythroid proteins were consistently increased in quantity in HbE/
b-thalassemic patients across all 3 pooled samples (Table 2), and
this was also observed in 6 individual samples (Table 4). Taken
together, the observed alterations in protein content in the
thalassemic EVs are consistent with the known increase in oxida-
tive burden due to peripheral hemolysis reported in previous
studies,13,22,24 and this study has substantially extended the
number of known proteins with an altered concentration in HbE/
b-thalassemic patients’ EVs.
The observed increased abundance of antioxidant and chaperone
proteins in thalassemic EVs was also observed by Ferru et al, who
detected alterations of Hsp70, PRDX2, and catalase.13 In our study,
we detected these proteins in at least twofold greater abundance in
thalassemic EVs when compared with EVs from control individuals.
The presence of these antioxidant proteins likely reflects the stress-
response mechanism in thalassemic erythrocytes, and we propose
this could be a result of either EVs shedding from the viable
erythrocytes or being generated from red cell lysis. This is also
consistent with the detection of RBC-specific proteins in EVs here
by us and by other studies.22
Chaperones are another group of proteins that exhibited an
increased abundance in the patients’ EVs. These proteins facilitate
the refolding of damaged proteins resulting from oxidative stress in
erythrocytes.25 AHSP, a specific erythroid chaperone significant in
erythropoiesis and exclusively binding to the a-hemoglobin chain,
has the greatest fold differences in patients’ EVs, consistent with
the known disturbance in b-globin in thalassemic erythrocytes.
Several genotype-phenotype studies exploring the association
between the AHSP gene and severity of thalassemia could not
identify any correlation.26-28 However, Bhattacharya et al22
reported an increase of AHSP expression in thalassemic
erythrocytes, which likely represents the original the source of
AHSP for EVs.
The proteomics also identified a higher quantity of ferritin and
transferrin receptor in EVs, 2 crucial iron-binding molecules.
Transferrin receptor is known to be lost during reticulocyte
maturation, suggesting that these may also be a source of EVs and
raised ferritin correlates with the increased iron status of the
patients (Table 1). This study focused on nontransfusion-
dependent thalassemic patients who develop iron overload due
to increased iron absorption and acceleration of iron released
from the reticuloendothelial system.29 The mean serum ferritin in
our study is 1035 ng/mL (normal value ,300 ng/mL, from 10 of
15 patients) with some patients requiring chelation. The height-
ened iron level observed in these patients represents an important
source of oxidative stress in thalassemic erythrocytes, which may
explain why EVs from thalassemic patients have more iron-binding
substances and antioxidant proteins in the plasma than healthy
individuals.
Haptoglobin and hemopexin are decreased in our patient EV
samples, and both are free hemoglobin and free-heme
scavenging plasma proteins, respectively. Free hemoglobin
and hemin, ferric hemoglobin, can unleash an oxidative
catastrophe to the vascular endothelium and parenchymal
tissue.30 These proteins bind these toxic substances and
transport them to the reticuloendothelial tissue to be
eliminated.30,31 Importantly, we demonstrated that circulating
Table 5. Statistical correlations between altered ratios of proteins of
interest and hemoglobin levels of 6 individual HbE/b-thalassemic
patients
Correlation coefficient P value, 2-tailed
Chaperone proteins
AHSP 20.943 .005**
Hsp70 20.829 .042*
HSPA8 20.543 .266
Hsp90 20.657 .156
TCP1-a 20.829 .042*
TCP1-g 20.714 .111
Antioxidants
Catalase 20.886 .019*
SOD1 20.886 .019*
PRDX2 20.886 .019*
Flavin reductase 20.829 .042*
Heme scavengers
Haptoglobin 0.371 .468
Hemopexin 0.714 .111
Other protein
Cathepsin S 20.543 .266
Negative correlation coefficients denote negative correlations.
*P , .05 represents statistical significance of .95%.
**P , .01 represents statistical significance of .99%.
Catalase
AHSP
Hemopexin
Haptoglobin
Coomassie stain
PT 1 CT 1 PT 2 CT 2
Figure 2. Western blot analysis of EV samples of 2 patients. Western blot
analysis of EV samples of 2 patients (PT 1 and PT 2; which are samples of EVs
isolated from patients 10 and 12, respectively) and EVs from 2 age-matched
controls (labeled CT 1 and CT 2) probed using antibodies to the indicated proteins.
In concordance with proteomics, the patients’ EVs had an increase in abundance of
AHSP and catalase when compared with control samples, and markedly decreased
haptoglobin and hemopexin protein levels. An example of Coomassie-stained gel is
shown to demonstrate the accuracy of loading.
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plasma EVs flexibly adsorb haptoglobin and hemopexin, thus
indirectly reflecting the availability and concentration of these
proteins in the plasma.
Overall, this report has undertaken the most detailed proteomic
study to date, describing the constituents of circulating EVs of HbE/
b-thalassemic patients, and providing quantitative differences of
protein expression in EVs in comparison with age- and sex-matched
healthy individuals. When compared with the pathophysiology of
the disease, the observed proteomic changes typify the protective
mechanisms used by the thalassemic patients. Antioxidants, iron-
sequestering proteins, and chaperones were the predominant
proteins that exhibited an increased abundance in thalassemic EVs.
We also report for the first time that the quantity of haptoglobin and
hemopexin, the free hemoglobin and heme-eliminating proteins, are
reduced in thalassemic patients’ EVs. Furthermore, the alteration of
levels of these proteins correlated with hemoglobin levels of the
patients (Tables 4 and 5). As far as we are aware, these plasma
proteins are not routinely tested for in the plasma of thalassemic
patients. Similar reductions in haptoglobin and hemopexin were
reported recently in the plasma of pediatric patients with sickle cell
disease32 and were proposed as potential biomarkers of clinical
severity of hemolysis in these patients. Thus, we have shown that
these plasma markers are also applicable for HbE/b-thalassemic
patients, where a deficit in haptoglobin and hemopexin availability
reflects the severity of systemic hemolysis. Finally, we have also
detected the altered levels of cathepsin S, a potent elastolytic
protease that could be useful as an inflammatory plasma marker to
monitor the degree of inflammation in thalassemia.23 Future studies
to evaluate the clinical application of these plasma biomarkers for
monitoring the severity of thalassemia and transfusion requirements
are now required.
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